Anti-TIM-3 Magnetic Beads-IP Kit Product Components
| Components | Storage |
| Anti-TIM-3 Magnetic Beads1,3 | 2-8℃ for 12 months |
| NP40 Cell Lysis Buffer2 | -20℃ for 12 months |
| 5×TBST（pH7.4） | |
| 1×TBST（pH7.4） | |
| ddH2O | |
| CD166 Positive Cell Lysate | -20℃ for 12 months |
| Alkaline Elution Buffer | 2-8℃ for 12 months |
| Acidity Elution Buffer | 2-8℃ for 12 months |
| Neutralization Buffer | 2-8℃ for 12 months |
[1] The IP KIT contains anti-TIM-3 magnetic Beads (2 mg/mL) in phosphate buffered saline (PBS, pH 7.4) with sodium azide (0.1%).
[2] Using NP-40 cell lysate buffer in the kit is required,otherwise,the magnetic beads may be precipitated.
[3] Shipping: Magnetic Beads kits are shipped at ambient temperature in which magnetic beads are provided in liquid buffer.
Anti-TIM-3 Magnetic Beads-IP Kit Product Description
The Anti-TIM-3 magnetic Beads, conjugated with Anti-TIM-3 antibody, are used for immuneprecipitation (IP) of TIM-3 proteins which expressed in vitro expression systems. For IP, the beads are added to a sample containing TIM-3 proteins to form a bead-protein complex. The complex is removed from the solution manually using a magnetic separator. The bound TIM-3 proteins are dissociated from the magnetic beads using an elution buffer. Anti-TIM-3 Magnetic Beads-IP Kit Antibody Information
Immunogen
Recombinant Mouse TIM-3 / HAVCR2 protein (Catalog#51152-M08H)
Species Reactivity
Mouse TIM-3 / HAVCR2
Source
Polyclonal Mouse Rabbit IgG
Preparation
Produced in rabbits immunized with purified, recombinant Mouse TIM-3 / HAVCR2 (rh TIM-3 / HAVCR2 ; Catalog#51152-M08H; AAL65156.1; Met1-Arg191). TIM-3 / HAVCR2 specific IgG was purified by Mouse TIM-3 / HAVCR2 affinity chromatography.
Applications
Immunoprecipitation (IP), Minimum Protein Purification
Anti-TIM-3 Magnetic Beads Immunoprecipitation (IP) Kit Alternative Names
Anti-TIM-3ALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit;Anti-Tim3ALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit;Anti-Timd3ALCAM Magnetic Beads-Immunoprecipitatiopn (IP) Kit
TIM-3 Background Information
Hepatitis A virus cellular receptor 2 (HAVCR2), formerly known as T cell immunoglobulin and mucin domain-3 (TIM-3), is a transmembrane glycoprotein expressed on the surface of terminally differentiated Th1 cells but not on Th2 cells. It was the first surface molecule that specifically identifies Th1 cells in both mice and human. Recently, identification of Galectin-9 as a ligand for TIM-3 has established the TIM-3-Galectin-9 pathway as an important regulator of Th1 immunity and tolerance induction. Engagement of Tim-3 by its ligand galectin-9 negatively regulates IFN-gamma secretion and influences the ability to induce T cell tolerance in both mice and man. It suggests a novel paradigm in which dysregulation of the TIM-3-galectin-9 pathway could underlie chronic autoimmune disease states, such as multiple sclerosis. Recent work has explored the role of TIM-3 in systemic lupus erythematosus (SLE), and their results indicate that TIM-3 may represent a novel target for the treatment of SLE. Numerous studies have demonstrated that Tim-3 influences autoimmune diseases, including diabetes and multiple sclerosis, and its role in other inflammatory diseases including allergies and cancer is beginning to become clear. In tumor rejection model, soluble form of Tim-3 (sTim-3) significantly impaired T cell antitumor immunity, evidenced by decreased antitumor CTL activity and reduced amount of tumor-infiltrating lymphocytes in tumor. sTim-3 as an immunoregulatory molecule that may be involved in the negative regulation of T cell-mediated immune response.
Immune Checkpoint Immune Checkpoint Detection: ELISA Antibodies Immune Checkpoint Detection: IP Antibodies Immune Checkpoint Detection: WB Antibodies Immune Checkpoint Proteins Immune Checkpoint Targets Co-inhibitory Immune Checkpoint Targets Immunotherapy Cancer Immunotherapy Targeted Therapy Full Name
hepatitis A virus cellular receptor 2
References
Geng H, et al. (2006) Soluble form of T cell Ig mucin 3 is an inhibitory molecule in T cell-mediated immune response. J Immunol. 176(3): 1411-20. Anderson AC, et al. (2006) TIM-3 in autoimmunity. Curr Opin Immunol. 18(6): 665-9. Anderson DE. (2007) TIM-3 as a therapeutic target in human inflammatory diseases. Expert Opin Ther Targets. 11(8): 1005-9. Pan HF, et al. (2010) TIM-3 as a new therapeutic target in systemic lupus erythematosus. Mol Biol Rep. 37(1): 395-8.
新浪微博
腾讯微博
QQ空间
客服
